Talicia (Omeprazole/Amoxicill/Rifabutin) Patent Expiration, LOE Window & CMS Spending

Talicia (Omeprazole/Amoxicill/Rifabutin) by Talicia Holdings: FDA Orange Book LOE 2042-05-27, 0 AB generics, $7.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTalicia Holdings
FDA Application & PathwayN213004 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2042-05-27
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$7.2M
2024 Medicare Part D Spend$2.6M
2024 Medicaid Spend$4.6M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 21.4% 2-yr change)